BPR-6023021

**BPR-6023021** is an undisclosed radioligand therapy in early clinical development for advanced solid tumors with bone metastases. It is being evaluated in a multicenter, open-label Phase I/II trial (NCT07249892) assessing safety, tolerability, pharmacokinetics, dosimetry, and preliminary efficacy when administered by injection at the recommended Phase 2 dose.[1][3][5][11] Developed initially by Chengdu Xinke Pharmaceutical Co Ltd and sponsored by Chengdu Syncor Pharmaceutical (also referred to as Chengdu Brilliant), the agent targets bone metastases in solid tumors, with IND approval achieved and first-in-human dosing scheduled around late 2025.[7][8][11]